G. Swensen et al., PATTERNS OF DRUG-USE BY PARTICIPANTS IN THE WESTERN-AUSTRALIAN METHADONE PROGRAM, 1984-1991, Medical journal of Australia, 159(6), 1993, pp. 373-376
Objectives: To establish the extent to which participants in the WA me
thadone treatment program used opiates, cannabinoids, benzodiazepines,
cocaine and amphetamines, and to define the pattern of such use over
time. In addition, the relationships between methadone dally dose and
the use of the various drug groups was examined. Design: A retrospecti
ve analysis of data from 1678 samples from urinalysis screening over 1
3 separate surveys between 1984 and 1991. A mean of 35.9% of patients
in the program was sampled on each occasion with each patient contribu
ting only one sample in any one survey. Analytical techniques used inc
luded enzyme-multiplied immunoassay, thin-layer chromatography and gas
chromatography-mass spectrometry. Results: Methadone and/or its major
metabolite were detected in most urine samples, indicating satisfacto
ry compliance by patients. The detection of opiates increased from a m
ean of 27.1% of samples in 1984-1989 to a mean of 44.2% of samples in
1990-1991. Codeine or morphine were most frequently detected (94% of a
ll opiate-positive samples) and were found together in 38.2% of opiate
-positive samples. Detection of cannabinoids also increased from a mea
n of 45.2% of all samples during 1984-1987 to a mean of 56.4% of sampl
es during 1990-1991. Benzodiazepines were found in a mean of 26.7% of
samples but use was not time-related. Detection of amphetamine-class d
rugs doubled from a mean of 8.3% of all samples (mid 1989 to mid 1990)
to 16.8% of samples (mid 1990 to mid 1991). The major representatives
of the latter group were methylamphetamine (47.3% of amphetamine-posi
tive urines), amphetamine (15.7%) and ephedrine/pseudoephedrine (44.6%
). Opiate use was significantly lower (P < 0.05) in those patients tak
ing more than 80 mg methadone/day. In addition, benzodiazepine use inc
reased significantly (P < 0.05) with increasing methadone daily dose.
There was no relationship between methadone daily dose and use of cann
abinoids or amphetamines. Conclusions: The increase in the use of opia
tes, cannabinoids and amphetamines over the period 1984-1991 occurred
about four years after the adoption of a harm minimisation treatment p
hilosophy by the WA methadone program. The high prevalence of codeine
and morphine in opiate-positive urine samples strongly suggested the u
se of ''home-bake'' heroin. In addition, the data showed that methylam
phetamine and ephedrine/pseudoephedrine were the most frequently used
psychostimulants. Suppression of opiate use in those clients receiving
more than 80 mg methadone/day was consistent with earlier studies. Ho
wever, the significant increase in use of benzodiazepines with increas
ing methadone daily dose requires further study.